NeoGenomics, Inc. provides a range of oncology diagnostic testing and consultative services which includes technical laboratory services. The Company offers professional interpretation of laboratory test results by licensed physicians who specialize in pathology and oncology. Its segments include Clinical Services and Advanced Diagnostics. The Clinical Services segment consists of clinical cancer testing; interpretation and consultative services; molecular and NGS testing, and comprehensive technical and professional services offering. Its Clinical Services customers include community-based pathology and oncology practices, hospital pathology labs, reference labs, and academic centers. The Advanced Diagnostics segment consist of clinical trials and research, validation laboratory services, and informatics. Its Advanced Diagnostics customers include pharmaceutical companies to whom it provides testing and other services to support their research studies and clinical trials.
BörsenkürzelNEO
Name des UnternehmensNeogenomics Inc
IPO-datumDec 10, 2012
CEOMr. Antony P. Zook
Anzahl der mitarbeiter2200
WertpapierartOrdinary Share
GeschäftsjahresendeDec 10
Addresse9490 Neogenomics Way
StadtFORT MYERS
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl33912
Telefon12397680600
Websitehttps://neogenomics.com/
BörsenkürzelNEO
IPO-datumDec 10, 2012
CEOMr. Antony P. Zook
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten